Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are up during Tuesday’s premarket session following positive interim results from one of its Phase 3 trials.
The stock’s rise comes as the company is reportedly making significant strides in its clinical development.
Vertex’s Phase 3 RAINIER Trial Success
Vertex announced that its ongoing Phase 3 RAINIER trial of povetacicept in immunoglobulin A nephropathy met its primary objective, achieving a 52% reduction from baseline in urine protein to creatinine ratio (UPCR) at Week 36.
Additionally, the trial demonstrated a statistically significant 49.8% UPCR reduction compared to placebo, with 85.1% of patients with baseline hematuria achieving resolution.
The positive data from the trial also showed that patients treated with povetacicept experienced a 77.4% reduction from baseline in serum galactose-deficient IgA1.
The FDA has granted a rolling review of the Biologics License Application for povetacicept, with Vertex planning to complete its full submission by the end of March.
Analyst Sees Clear Win For Vertex
William Blair wrote on Tuesday, “Overall, the Phase III RAINIER proteinuria data is a clear win for Vertex…we believe these data are supportive of a best-in-class product for the BAFF/APRIL inhibitors.”
Analyst Myles Minter increased the probability of success from 70% to 90% ahead of BLA submission completion by the end of March, expected priority review under the voucher program, and potential approval by year-end.
William Blair does not anticipate material revenue from povetacicept in IgAN until 2027, pending reimbursement dynamics and formulary placements.
Technical Analysis
Currently, Vertex Pharmaceuticals is trading 2.2% above its 20-day simple moving average (SMA) and 7.8% above its 100-day SMA, demonstrating longer-term strength. Shares have decreased 7.83% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 44.56, which is considered neutral territory. Meanwhile, MACD is at 0.0109, below its signal line at 3.2118, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $498.00
- Key Support: $454.50
Analyst Consensus & Recent Actions
The stock carries a Buy Rating with an average price target of $523.96. Recent analyst moves include:
- Canaccord Genuity: Hold (Raises Target to $441.00) (Feb. 17)
- Barclays: Overweight (Raises Target to $607.00) (Feb. 17)
- HC Wainwright & Co.: Buy (Raises Target to $591.00) (Feb. 17)
VRTX’s Significant ETF Exposure
- Pacer S&P 500 Quality FCF R&D Leaders ETF (NASDAQ:QFRD): 3.43% Weight
- iShares Biotechnology ETF (NASDAQ:IBB): 8.70% Weight
- VanEck Biotech ETF (NASDAQ:BBH): 9.12% Weight
VRTX Price Action: Vertex Pharmaceuticals shares were up 6.32% at $489.99 during premarket trading on Tuesday.
Image via Shutterstock
This article Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps originally appeared on Benzinga.com
.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
VIPMiddle East Tensions Raise Rate Risks but May Create Buying Opportunities
1. The sharp escalation in Middle East tensions pushed Brent crude to multi-year highs of $105–$107 per barrel, reviving inflation expectations. The 10-year U.S. Treasury yield surged to 4.94%, its highest level since 2023, while the implied probability of a rate hike at the September 16 policy meeting to the 3.75%–4.00% range rose from 48.4% one month ago to 67.1%. 2. Rising oil prices and rate-hike expectations weighed on most risk assets, but historical data suggest that this is more likely to be a short-term adjustment than a reversal of the broader trend. Bitcoin fell 3.36% this week and the S&P 500 declined 1.64%, while gold slipped just 0.96%. Outside the energy sector, markets are largely repricing ahead of next week's expected rate decision. 3. PoolX has recently introduced a long-term holding bonus, significantly improving effective returns for users who maintain assets on the platform over time. The core participation rules remain unchanged; the update adds an additional boost to the effective locked amount for users with qualifying long-term holdings. In the example provided, a user locking 1000 ETH would see the estimated reward increase from 1666.67 USDT to 2500 USDT, or about 50%, while the reference APR rises from 4.93% to 7.40%. Assets to watch: BTC, ETH, SOL, Brent crude, WTI crude, gold, 10-year U.S. Treasuries, RAY, ZEC, LEN, CCL.
NASDAQ TRADE HALT CONTINUES <EFTY.O> REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES <NRSN.O> REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT <NFEGP.O> REASON NOT AVAILABLE AT 03:58 AM
Crypto prices
More
